ClinicalTrials.Veeva

Menu

Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA

Yonsei University logo

Yonsei University

Status

Enrolling

Conditions

Bladder Cancer
Ureter Cancer
Renal Cell Cancer
Prostate Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT04197414
4-2019-1039

Details and patient eligibility

About

Urological malignancies such as prostate cancer and renal cell cancer in Korean population have been increased due to the aged population and the westernized lifestyles. With the advancement of sequencing technologies, use of genetic mutation profiles in cancer detection and progression has been increased. However, use of circulating tumor DNA in urological malignances have been limited and few studies have been reported. Therefore, we tried to evaluate the usefulness of circulating tumor DNA in detection and monitoring of urological malignancies in Korean population. This study aims to use circulating tumor DNA in plasma and urine for the diagnosis, disease progression monitoring and therapeutic response evaluation. This study plan includes building big databases for circulating tumor DNA of urological malignancies in Korean population and to develop optimized circulating tumor DNA platform.

Enrollment

3,000 estimated patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

    1. Patients diagnosed as urological malignances (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer)
    1. Patients who have undergone surgeries due to urological malignancies in Severance Hospital, Sinchon from 2019.12 and 2029.11
    1. Those who agree to give permission to use their human source information - 4. Those who agree with this study

Exclusion criteria

    1. Those who do not agree with this study
    1. Vulnerable participants who are likely to be vulnerable to coercion or undue influence or lack decision-making

Trial design

3,000 participants in 4 patient groups

Prostate cancer
Description:
Patients diagnosed as prostate cancer and have undergone prostatectomy
Renal cell cancer
Description:
Patients diagnosed as renal cell cancer and have undergone partial or radical nephrectomy
Bladder cancer
Description:
Patients diagnosed as bladder cancer and have undergone radical or partial cystectomy
Ureter cancer
Description:
Patients diagnosed as ureter cancer and have undergone nephroureterectomy or ureterectomy

Trial contacts and locations

1

Loading...

Central trial contact

Won Sik Ham

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems